# GH-Axis Peptide FAQ — Ipamorelin, CJC-1295, Sermorelin — Peptide Division

> Frequently asked questions about three Growth Hormone Axis research peptides — ipamorelin, CJC-1295, and sermorelin — answered directly from the peer-reviewed literature, with numbered citations.

What readers most often ask about ipamorelin, CJC-1295, and sermorelin — answered from the published record, not from community consensus.

## What is ipamorelin?

Ipamorelin is a synthetic five-amino-acid (pentapeptide) research compound that selectively activates the ghrelin/growth hormone secretagogue receptor (GHS-R1a) on pituitary cells, triggering a pulse of growth hormone release. Its defining property is selectivity: it releases GH comparably to earlier GHRPs but without the cortisol and prolactin elevation those compounds produce [6]. It is not an approved drug anywhere and is sold for laboratory research use only.

## What does ipamorelin do for you?

That question assumes a clinical benefit established in humans — which the record does not support for any indication. In healthy volunteers, IV ipamorelin produced a dose-dependent GH pulse peaking roughly 40 minutes after dosing [4]. In a Phase 2 trial of 114 adults recovering from bowel surgery, it did not significantly reduce time to first tolerated meal compared to placebo (primary endpoint not met, p=0.15) [3]. Common community claims — improved sleep, recovery, body composition — are anecdotal and not established by controlled trials. This site does not describe personal benefits or advise on use.

## What is ipamorelin peptide?

"Ipamorelin peptide" is informal language for ipamorelin — a synthetic peptide with the chemical sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. The unusual amino acids at positions 1, 3, and 4 (alpha-aminoisobutyric acid and D-configured residues) resist enzymatic breakdown, giving the compound a usable pharmacokinetic window despite being a small molecule. It was characterized in 1998 as the first highly GH-selective growth hormone secretagogue [6].

## What are the risks of ipamorelin?

The documented and reasoned risk signals are these. First, a 28-day preclinical study of a structurally distinct but pharmacologically related GHS-R1a agonist found dose-dependent myocardial degeneration in rats — a class-level cardiovascular signal without a human counterpart [2]. Second, GH counter-regulates insulin; ipamorelin also has GH-independent insulinotropic effects on pancreatic tissue, creating unpredictable glycemic impact in subjects with insulin resistance [6]. Third, there are no long-term human safety data — the only controlled human studies lasted 7 days (Phase 2 trial) or used acute single-dose IV infusions [3][4]. Fourth, research-grade material from unregulated suppliers is not quality-assured for purity or identity.

## What is CJC-1295?

CJC-1295 is a long-acting synthetic analog of growth hormone-releasing hormone (GHRH), built on the first 29 residues of the natural molecule with four stabilizing amino-acid substitutions. The DAC (Drug Affinity Complex) variant adds an albumin-binding moiety that extends its half-life to approximately 5.8–8.1 days, sustaining GH and IGF-1 elevation from a single dose for days [11]. The no-DAC variant (Modified GRF 1-29) carries only the stabilizing substitutions and has a much shorter half-life. CJC-1295 is a research compound, not an approved drug.

## What does CJC-1295 do?

In two published human pharmacology studies, CJC-1295 produced sustained, dose-dependent elevation of both GH and IGF-1 while preserving pulsatile GH secretion [11][12]. A single subcutaneous dose raised mean plasma GH two- to ten-fold for six or more days and kept IGF-1 above baseline for 9–11 days. Basal GH rose approximately 7.5-fold in a second study. These are pharmacokinetic and pharmacodynamic observations in healthy volunteers — there is no completed controlled trial of what CJC-1295 does to any disease state, body-composition outcome, or aging parameter.

## Is CJC-1295 safe?

The published human data — two small PK studies in healthy volunteers — do not report significant adverse events, but they are short-term pharmacology observations, not safety trials. No long-term human safety study of CJC-1295 has been conducted. Relevant theoretical concerns include IGF-1-driven oncologic risk from sustained elevation, sodium retention, and insulin sensitivity effects — the same axis effects that make GH excess (acromegaly) a serious clinical condition [8]. The FDA's 2024 Pharmacy Compounding Advisory Committee review cited immunogenicity and safety concerns for this compound class.

## How much CJC-1295 should I take?

This desk does not advise on human doses. The published human PK studies used subcutaneous doses of 30–90 micrograms/kg in healthy research volunteers [11][12] — those are pharmacology study parameters, not treatment recommendations. CJC-1295 is a research compound with no approved human indication. Any dosing protocol in clinical or community use is outside the peer-reviewed evidence base.

## What is sermorelin?

Sermorelin is a synthetic 29-amino-acid peptide corresponding to the N-terminal bioactive fragment of growth hormone-releasing hormone (GHRH(1-29)). It is the shortest GHRH fragment that retains full receptor activity. It was previously FDA-approved as a drug for pediatric growth hormone deficiency, commercially withdrawn in 2008 for business reasons (not a safety or efficacy failure), and is now prepared by compounding pharmacies under FDA's Category 1 interim 503A policy [15][16].

## What does sermorelin do to the body?

Sermorelin binds the GHRH receptor on anterior-pituitary somatotrophs and activates cAMP/PKA signaling to stimulate pulsatile growth hormone release — the body's own GH, under its own feedback regulation, rather than exogenous GH supplied from outside. In prepubertal children with GH deficiency, once-daily subcutaneous sermorelin raised first-year height velocity from approximately 4.1 cm/year to roughly 7–8 cm/year [16]. In adults, the strongest RCT data for the mechanism class comes from a related compound (tesamorelin, not sermorelin) and showed favorable cognitive effects and body-fat reduction in older adults over 20 weeks [13].

## Does sermorelin work?

For its approved indication — pediatric growth hormone deficiency — the controlled evidence says yes: a multicenter trial demonstrated significantly accelerated linear growth [16]. For adult anti-aging or wellness use, an Annals of Internal Medicine editorial explicitly judged GH-secretagogue interventions for aging "not yet ready for prime time" [14]. Marketing claims for adult body recomposition or anti-aging are not backed by controlled efficacy trials of sermorelin in healthy adults. "Does it work" depends heavily on for what.

## How long does it take for sermorelin to work?

Mechanistically, sermorelin acts quickly — it binds the GHRH receptor and triggers a GH pulse within the time frame of normal pituitary signaling. Whether any downstream physiologic change follows, and over what timescale, depends on the indication and the individual. In the pediatric GH-deficiency trial, height-velocity changes were measured over a full year [16]. In healthy adults, this question is largely uncharacterized in controlled studies — there are no published sermorelin-specific human trials reporting response timelines for body composition, cognition, or any other adult endpoint.

---

Peer-reviewed literature on the GH axis, summarized as a reading desk — not a vendor, not a clinic, and never a prescription.